Recent advances in the diagnosis of drug-induced liver injury.
Diagnosis
Drug induced liver injury
Liver biopsy
RECAM
RUCAM
Journal
World journal of hepatology
ISSN: 1948-5182
Titre abrégé: World J Hepatol
Pays: United States
ID NLM: 101532469
Informations de publication
Date de publication:
27 Feb 2024
27 Feb 2024
Historique:
received:
29
09
2023
revised:
03
01
2024
accepted:
03
02
2024
medline:
18
3
2024
pubmed:
18
3
2024
entrez:
18
3
2024
Statut:
ppublish
Résumé
Drug-induced liver injury (DILI) is a major problem in the United States, commonly leading to hospital admission. Diagnosing DILI is difficult as it is a diagnosis of exclusion requiring a temporal relationship between drug exposure and liver injury and a thorough work up for other causes. In addition, DILI has a very variable clinical and histologic presentation that can mimic many different etiologies of liver disease. Objective scoring systems can assess the probability that a drug caused the liver injury but liver biopsy findings are not part of the criteria used in these systems. This review will address some of the recent updates to the scoring systems and the role of liver biopsy in the diagnosis of DILI.
Identifiants
pubmed: 38495272
doi: 10.4254/wjh.v16.i2.186
pmc: PMC10941738
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
186-192Informations de copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.